All In Biotech

Drug Trial Radar · NCT06846671

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Apr 10, 2025

Primary completion

May 15, 2028

Study completion Feb 14, 2030

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Feb 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).

Conditions

  • CLL
  • Chronic Lymphocytic Leukemia
  • SLL

Interventions

  • TacabrutidegDrug

    Administered orally

  • BendamustineDrug

    Administered intravenously

  • IdelalisibDrug

    Administered orally

  • RituximabDrug

    Administered intravenously

  • VenetoclaxDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) by Independent Review Committee (IRC)Time frame: Approximately 36 Months

Locations

134 sites in 14 countries. Site status is shown where the registry gives one.

  • St Bernards Medical Center

    Jonesboro, Arkansas · Recruiting

  • UCLA Department of Medicine Hematologyoncology

    Los Angeles, California · Recruiting

  • Scripps Prebys Cancer Center

    San Diego, California · Recruiting

  • Pih Health Whittier Hospital

    Whittier, California · Recruiting

  • Rocky Mountain Cancer Centers (Williams) Usor

    Aurora, Colorado · Recruiting

  • Intermountain Health Lutheran Hospital Cancer Center of Colorado

    Golden, Colorado · Recruiting

  • Florida Oncology and Hematology

    Fort Myers, Florida · Recruiting

  • Baptist Md Anderson Cancer Center

    Jacksonville, Florida · Recruiting

  • Cleveland Clinic Florida

    Weston, Florida · Recruiting

  • Emory University Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Northside Cancer Center

    Atlanta, Georgia · Recruiting

  • Our Lady of the Lake Hospital

    Baton Rouge, Louisiana · Recruiting

  • American Oncology Partners of Maryland Pa

    Bethesda, Maryland · Recruiting

  • Corewell Health the Michigan Cancer Consortium

    Grand Rapids, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • St Lukes Center For Cancer Care

    Chesterfield, Missouri · Recruiting

  • Oncology Hematology Associates

    Springfield, Missouri · Recruiting

  • St Vincent Frontier Cancer Center

    Billings, Montana · Recruiting

  • Oncology Hematology West, Pc Dba Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Memorial Sloan Kettering Cancer Center Mskcc

    New York, New York · Recruiting

  • New York Cancer and Blood Specialists

    Shirley, New York · Recruiting

  • Suny Upstate Medical University

    Syracuse, New York · Recruiting

  • Optum Medical Care, Pc

    Westbury, New York · Recruiting

  • University Hospitals

    Cleveland, Ohio · Recruiting

  • Dayton Physician Network

    Dayton, Ohio · Recruiting

  • Oncology Associates of Oregon Willamette Valley Cancer Center

    Eugene, Oregon · Recruiting

  • West Penn Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • Cancer Care Associates of York

    York, Pennsylvania · Recruiting

  • Baylor Scott and White Health Medical Center Temple

    Temple, Texas · Recruiting

  • Texas Oncology Tyler

    Tyler, Texas · Recruiting

  • Hospital Aleman

    Caba, Argentina · Recruiting

  • CEMIC

    Caba, Argentina · Recruiting

  • FUNDALEU

    Caba, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming (Iaf)

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Cice 9 de Julio Sanatorio 9 de Julio

    San Miguel de Tucumán, Argentina · Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia · Recruiting

  • Gosford Hospital

    Gosford, New South Wales, Australia · Recruiting

  • Port Macquarie Base Hospital

    Port Macquarie, New South Wales, Australia · Recruiting

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia · Recruiting

Showing 40 of 134 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.